Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BED003

Radiopharmaceutical

Phase 2 Most advanced trial

1 Registered trials

What is BED003?

BED003 is a gallium-68 labeled radiopharmaceutical for positron emission tomography/computed tomography imaging. It is being studied in colorectal cancer, epithelial ovarian cancer, gastric cancer, pancreatic ductal adenocarcinoma, and invasive lobular breast carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Radiopharmaceutical
Therapy area: Oncology
In trials of: MEDP
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07702292	Phase 2	Colorectal Cancer	Recruiting	MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerEpithelial Ovarian CancerGastric Cancer (GC)Invasive Lobular Breast CarcinomaPancreatic Ductal Adenocarcinoma (PDAC)

Sources

ClinicalTrials.gov NCT07702292

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z